Endocrine TumoreurocrineNCT03410394
Registry of Endocrine Tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube)
An observational study of Endocrine Tumor, run by Central Hospital, Nancy, France at 1 site in France.
Trial summary
This registry aims to collect informations about patients with endocrine tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube) who undergo endocrine surgical procedures. This registry is part of the Eurocrine Project. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Endocrine Tumor
- How many people
- 3,000 participants
- Where
- 1 siteFrance
- Study dates
- 1 Jan 2015to 1 Jan 2030
- How long will I take part?
- 10 Years
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: patients who undergo surgical procedures for endocrine tumors at CHU Nancy Brabois (University hospital)
Who may be able to join
- patients who undergo surgical procedures for endocrine tumors at the University Nancy Brabois Hospital
Who cannot join
- unable to receive clear information
- refusal to sign the consent form
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
laurent Brunaud, MD, PhD contact
Brunaud contact
France1 site, 1 recruiting
- Recruiting
CHU Nancy
Vandœuvre-lès-Nancy, 54511
laurent Brunaud, l.brunaud@chu-nancy.fr
About this study
Official title: Registre Tumeurs Endocrine - Eurocrine
This registry aims to collect informations about patients with endocrine tumors (Thyroid, Parathyroid, Adrenal, Endocrine Pancreas, Endocrine Digestive Tube) who undergo endocrine surgical procedures. This registry is part of the Eurocrine Project.
Read the detailed description
The EUROCRINE project aims to decrease morbidity and mortality of rare endocrine tumours, by means of a pan-European database. Recording and accessing data at the European level, makes it possible to identify these tumours, which cannot be distinguished at local or national level, because of their extreme rarity. Dissemination of results aims to raise clinical standards and reduce differences in practise between clinics and member states, and thereby diminish morbidity and mortality. Comparison of practice and outcomes will be especially interesting for centres wanting to improve their standards to what is currently considered best practice. EUROCRINE will be a key means by which the medical profession, researchers, health policy makers, and not least patients, can benefit from an increase in knowledge related to diagnosis, treatment, and future clinical research in the field of rare endocrine tumours.
- Conditions
- Endocrine Tumor
- Keywords
- adrenal, thyroid, parathyroid, endocrine pancreas, endocrine digestive tube
- Medical subject headings
- Endocrine Gland Neoplasms, Thyroid Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| registry of endocrine tumors | * Patients who undergo thyroid surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-22. * Patients who undergo parathyroid surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-23 * Patients who undergo adrenal surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-24 * Patients who undergo pancreatic and digestive surgical procedures. This registry was declared at the commission national informatique et libertés (CNIL) with the number R2015-26 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative complications (endocrine surgical procedure)
morbidity rate in percentage (%)
Measured: 12 months after surgical procedure
Secondary outcomes (13)
Postoperative complications severity (endocrine surgical procedure)
Dindo-Clavien classification in percentage (%)
Measured: 12 months after surgical procedure
Postoperative mortality (endocrine surgical procedure)
mortality rate in percentage (%)
Measured: 12 months after surgical procedure
CT imaging before endocrine surgical procedure (Tumor characteristics)
Density in Hounsfield unit (HU)
Measured: Baseline
CT imaging before endocrine surgical procedure (Coronary artery score)
CAC score in Agatston score unit (HU)
Measured: Baseline
CT imaging before endocrine surgical procedure (Sarcopenia)
Evaluation of sarcopenia using L3 skeletal muscle index (in cm²/m²)
Measured: preoperative period
Bone mineral density
dual-energy x-ray absorptiometry (DEXA) (in T-score unit)
Measured: Baseline
Intraoperative systolic arterial pressure
systolic arterial pressure (in mmHg)
Measured: Intraoperative
Intraoperative diastolic arterial pressure
diastolic arterial pressure (in mmHg)
Measured: Intraoperative
Parathormone plasma levels
Parathormone (in pg/mL)
Measured: Baseline and up to 12 months after surgical procedure
Aldosterone plasma levels
Aldosterone (in pmol/L)
Measured: Baseline and up to 12 months after surgical procedure
Plasma renin activity
Renin (in μIU/mL)
Measured: Baseline and up to 12 months after surgical procedure
Plasma free metanephrines
metanephrines (in nmol/L)
Measured: Baseline and up to 12 months after surgical procedure
PET scanning
standardized uptake values (SUV tumor / SUV liver ratio)
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jan 2018
- Study start1 Jan 2015
- Primary completion1 Jan 2030 (estimated)
- Study completion1 Jan 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Endocrine TumorStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,000 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Central Hospital, Nancy, France
- Sponsor type
- University, hospital or other
- Collaborators
- Association Francophone de Chirurgie Endocrinienne (AFCE), European Society of Endocrine Surgery (ESES)
- Responsible party
- Principal investigator, Laurent BRUNAUD, Central Hospital, Nancy, France
- Investigators
- laurent Brunaud, Principal investigator, University of Lorraine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03410394
- Sponsor's protocol ID
- N° CCTIRS :15.291 Version N°3
- Acronym
- eurocrine
- Status last verified
- Oct 2026
- First submitted
- 10 Jan 2018
- Last updated
- 22 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Remond A, Marciniak C, Lenne X, Chouraki V, Gobert M, Baud G, Maillard L, Bouriez D, Liekens E, Donatini G, Nomine-Criqui C, Ravenet A, Santucci N, Kuczma P, Bouviez N, Tresallet C, Mirallie E, Deguelte S, Brunaud L, Guerin C, Gronnier C, Lifante JC, Bruandet A, Theis D, Cortot A, Scherpereel A, Hamroun A, Pattou F, Caiazzo R. Survival and Prognostic Factors After Adrenalectomy for Secondary Malignancy: A Combined Analysis of a French University Center Registry (Eurocrine) of 307 Patients and a French Nationwide Study of 2515 Patients. Ann Surg. 2024 Nov 1;280(5):825-834. doi: 10.1097/SLA.0000000000006479. Epub 2024 Aug 7.
PubMed 39109429Greilsamer T, Nomine-Criqui C, Thy M, Ullmann T, Zarnegar R, Bresler L, Brunaud L. Robotic-assisted unilateral adrenalectomy: risk factors for perioperative complications in 303 consecutive patients. Surg Endosc. 2019 Mar;33(3):802-810. doi: 10.1007/s00464-018-6346-2. Epub 2018 Jul 11.
PubMed 29998394